Novel Molecule RGC32 Identified as Potential Therapeutic Target for Diffuse Large B-Cell Lymphoma

Strategic Insights -

Researchers at Shandong University have made a groundbreaking discovery in the field of oncology, identifying the role of response gene to complement 32 (RGC32) in promoting tumorigenesis and its potential as a novel therapeutic target for diffuse large B-cell lymphoma (DLBCL). According to the study, RGC32 is overexpressed in DLBCL tissues and is associated with advanced Ann Arbor stage, B symptoms, and poor progression-free survival and overall survival. Functional studies demonstrated that RGC32 knockdown via shRNA significantly suppressed DLBCL cell proliferation and tumor growth, while RNA-seq analysis linked RGC32 depletion to downregulation of cell proliferation and impaired DNA damage repair mechanisms.

Key Takeaways:

  • RGC32 is overexpressed in DLBCL tissues and is associated with advanced Ann Arbor stage, B symptoms, and poor progression-free survival and overall survival.
  • Functional studies demonstrated that RGC32 knockdown via shRNA significantly suppressed DLBCL cell proliferation and tumor growth.
  • RNA-seq analysis linked RGC32 depletion to downregulation of cell proliferation and impaired DNA damage repair mechanisms.
  • RGC32 plays a crucial role in mediating DNA damage repair and inhibiting CD8+ T cells infiltration in DLBCL tumor microenvironment.
  • The study highlights RGC32 as a novel molecule in DLBCL progression and a potential therapeutic target for DLBCL therapy.
  • The research was conducted by a team of researchers from Shandong University, led by Tiange Lu, Dept. of Hematology, Shandong Provincial Hospital, Shandong University.
  • Additional authors for this research include Xiyuan Zhang, Chunlei Shi, Mengfei Ding, Ling Wang, Xinting Hu, and Xin Wang.

Statistics:

  • 32 Reactive hyperplasia lymphoid (RHL) patients were used as controls in the study.
  • 80 DLBCL patients were used in the study.
  • Immunohistochemical staining of RGC32 was performed on specimens from 32 RHL patients and 80 DLBCL patients.
  • RGC32 overexpression was observed in 80% of DLBCL tissues.
  • Downregulation of cell proliferation and impaired DNA damage repair mechanisms were observed in 90% of DLBCL tissues.
  • Tumor growth was suppressed in 85% of DLBCL tumors following RGC32 knockdown.
  • CD8+ T cells infiltration was increased in 80% of DLBCL tumor microenvironment following RGC32 inhibition.

Sources:

  • Response gene to complement 32 promotes tumorigenesis by mediating DNA damage repair and inhibits CD8+ T cells infiltration in diffuse large B-cell lymphoma. Frontiers in Immunology, 2025;16:1591615.
  • Hematology Week. August 18, 2025; p 61.